NEOGAP Therapeutics AB
Samuel Svensson is an accomplished professional with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as CEO of NEOGAP Therapeutics AB and CBD Solutions AB, as well as Chairman of Biopercept AB, Svensson has demonstrated leadership and innovation since April 2016 and April 2013, respectively. Previous roles include Co-Founder and Senior Principal Scientist at Alzecure Foundation and Principal Scientist at AstraZeneca R&D, contributing to significant advancements in research and development from 2002 to 2012. Additionally, Svensson held an Associate Professorship at Linköping University from 1995 to 2002 and continues to serve as a Professor at the same institution, highlighting a strong academic foundation and commitment to scientific excellence.
This person is not in any offices
NEOGAP Therapeutics AB
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.